New Treatments for HR-Positive Breast Cancer and Mantle Cell Lymphoma Offer Promising Outcomes and Expanded Options for ...

Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...

A landmark study overturns common beliefs about breast cancer surgery, revealing new insights into treatment choices and ...

On January 17, 2025, the Food and Drug Administration (FDA) approved datopotamab deruxtecan-dlnk a Trop-2-directed antibody ...

Cite this: SABCS 2024: New Treatment Options in HR+/HER2- Breast Cancer - Medscape - Jan 10, 2025.

Discover the 3 critical warning signs of breast cancer that every Black woman should know, plus insights on early detection ...

Breast cancer is the second leading cause of cancer death in women. Early detection results in 99% five-year survival rates.

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by ...

Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.

Genetic testing is recommended for those with personal and family histories of several types of cancer — including pancreatic ...

Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

Dawn Klemow, MD, assistant clinical professor, University of Texas Southwestern Medical Center, previews some of the most recent advances in breast cancer treatment.